What are the prescription templates for managing and treating various types of seizures, including generalized tonic-clonic seizures, absence seizures, complex partial seizures, and simple partial seizures, using antiepileptic drugs (AEDs) such as valproate (Valproic Acid), lamotrigine (Lamictal), levetiracetam (Keppra), ethosuximide (Zarontin), carbamazepine (Tegretol), oxcarbazepine (Trileptal), and topiramate (Topamax)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Prescription Templates for Seizure Management

Status Epilepticus Management

For any patient actively seizing, immediately administer IV lorazepam 4 mg at 2 mg/min as first-line treatment, which demonstrates 65% efficacy in terminating status epilepticus. 1

First-Line Treatment (Active Seizures)

  • Lorazepam 4 mg IV at 2 mg/min - preferred benzodiazepine due to longer duration of action 1
  • Check fingerstick glucose immediately and correct hypoglycemia while administering treatment 1
  • If IV access unavailable, use rectal diazepam as alternative 2

Second-Line Treatment (Seizures Continuing After Benzodiazepines)

After adequate benzodiazepine dosing, administer one of the following agents based on patient-specific factors: 3, 1

Option 1: Valproate (Preferred for Safety Profile)

  • Dose: 20-30 mg/kg IV over 5-20 minutes 1
  • Efficacy: 88% seizure control 1
  • Hypotension risk: 0% 1
  • Maintenance: 1-2 mg/kg/hour continuous infusion 2
  • Prescription Template:
    Valproate 20-30 mg/kg IV (max 3000 mg)
    Infuse over 5-20 minutes
    Follow with maintenance infusion 1-2 mg/kg/hour
    Monitor: Liver function, platelets, ammonia

Option 2: Fosphenytoin (Most Widely Available)

  • Dose: 20 mg PE/kg IV at maximum rate of 150 PE/min 1
  • Efficacy: 84% seizure control 1
  • Hypotension risk: 12% 1
  • Requires continuous ECG and blood pressure monitoring 1
  • Prescription Template:
    Fosphenytoin 20 mg PE/kg IV (max 1500 mg PE)
    Infuse at maximum rate 150 PE/min
    Continuous cardiac monitoring required
    Monitor: Blood pressure, ECG, phenytoin level

Option 3: Levetiracetam (Minimal Cardiovascular Effects)

  • Dose: 30 mg/kg IV over 5 minutes 1
  • Efficacy: 68-73% seizure control 1
  • Minimal drug interactions, no serum level monitoring required 2
  • Prescription Template:
    Levetiracetam 30 mg/kg IV (max 3000 mg)
    Infuse over 5 minutes
    Monitor: Behavioral changes, somnolence

Option 4: Phenobarbital

  • Dose: 20 mg/kg IV over 10 minutes 1
  • Efficacy: 58.2% seizure control 1
  • Higher risk of respiratory depression 1
  • Prescription Template:
    Phenobarbital 20 mg/kg IV (max 1500 mg)
    Infuse over 10 minutes
    Monitor: Respiratory status, blood pressure
    Prepare for possible intubation

Third-Line Treatment (Refractory Status Epilepticus)

Refractory status epilepticus is defined as seizures continuing despite benzodiazepines and one second-line agent; initiate continuous EEG monitoring at this stage. 1

Option 1: Midazolam Infusion (First Choice for Refractory SE)

  • Loading dose: 0.15-0.20 mg/kg IV 1
  • Continuous infusion: 1 mg/kg/min 1
  • Titrate up by 1 mg/kg/min every 15 minutes to maximum 5 mg/kg/min 1
  • Efficacy: 80% overall success rate 1
  • Hypotension risk: 30% 1
  • Prescription Template:
    Midazolam 0.15-0.20 mg/kg IV bolus
    Follow with continuous infusion 1 mg/kg/min
    Titrate by 1 mg/kg/min every 15 minutes
    Maximum rate: 5 mg/kg/min
    Monitor: Continuous EEG, blood pressure, respiratory status
    Load phenytoin/valproate/levetiracetam during infusion

Option 2: Propofol (For Intubated Patients)

  • Loading dose: 2 mg/kg bolus 1
  • Continuous infusion: 3-7 mg/kg/hour 1
  • Efficacy: 73% seizure control 1
  • Hypotension risk: 42% 1
  • Requires mechanical ventilation but shorter ventilation time (4 days vs 14 days with pentobarbital) 1
  • Prescription Template:
    Propofol 2 mg/kg IV bolus
    Follow with continuous infusion 3-7 mg/kg/hour
    Titrate to EEG burst suppression
    Monitor: Continuous blood pressure, EEG, triglycerides
    Mechanical ventilation required

Option 3: Pentobarbital (Highest Efficacy, Most Hypotension)

  • Loading dose: 13 mg/kg 1
  • Continuous infusion: 2-3 mg/kg/hour 1
  • Efficacy: 92% seizure control 1
  • Hypotension risk: 77% 1
  • Prescription Template:
    Pentobarbital 13 mg/kg IV bolus
    Follow with continuous infusion 2-3 mg/kg/hour
    Titrate to EEG burst suppression
    Monitor: Continuous blood pressure, EEG
    Prepare for vasopressor support
    Mechanical ventilation required

Generalized Tonic-Clonic Seizures (Chronic Management)

For chronic management of generalized tonic-clonic seizures, sodium valproate is the first-line treatment, with lamotrigine and levetiracetam as suitable alternatives, particularly for those of childbearing potential. 4, 5

First-Line Monotherapy Options

Option 1: Valproate (Treatment of Choice)

  • Starting dose: 15 mg/kg/day in divided doses 6
  • Increase by 5-10 mg/kg/week to achieve optimal response 6
  • Target dose: Usually below 60 mg/kg/day 6
  • Therapeutic level: 50-100 μg/mL 6
  • Prescription Template:
    Valproic Acid 250 mg PO TID (for 60 kg patient = 12.5 mg/kg/day)
    Increase by 250 mg every week as tolerated
    Target dose: 1000-1500 mg daily in divided doses
    Monitor: Liver function, CBC, ammonia, valproate level
    Contraindicated in pregnancy

Option 2: Lamotrigine (Alternative, Especially for Women of Childbearing Age)

  • Starting dose: 25 mg daily for 2 weeks (when not on enzyme inducers) 4, 5
  • Slow titration required to minimize rash risk 4, 5
  • Prescription Template:
    Lamotrigine 25 mg PO daily x 2 weeks
    Then 50 mg daily x 2 weeks
    Then 100 mg daily x 1 week
    Target maintenance: 200-400 mg daily in 1-2 divided doses
    Monitor: Rash (discontinue if develops), liver function
    Slower titration if on valproate

Option 3: Levetiracetam (Alternative with Minimal Drug Interactions)

  • Starting dose: 500 mg twice daily 4, 5
  • Increase by 500 mg every 2 weeks 4, 5
  • Prescription Template:
    Levetiracetam 500 mg PO BID
    Increase to 1000 mg BID after 2 weeks
    Target maintenance: 1000-1500 mg BID
    Monitor: Behavioral changes, mood disturbances
    No serum level monitoring required

Option 4: Topiramate (Second-Line)

  • Starting dose: 25-50 mg daily 7
  • Increase by 25-50 mg weekly 7
  • Prescription Template:
    Topiramate 25 mg PO daily x 1 week
    Then 50 mg daily x 1 week
    Then 100 mg daily x 1 week
    Target maintenance: 200-400 mg daily in 2 divided doses
    Monitor: Cognitive effects, weight loss, kidney stones

Complex Partial Seizures (Focal Seizures with Impaired Awareness)

For complex partial seizures, carbamazepine and oxcarbazepine are treatments of choice, with lamotrigine and levetiracetam also as first-line options. 7, 4, 5

First-Line Monotherapy Options

Option 1: Oxcarbazepine (Treatment of Choice)

  • Starting dose: 300 mg twice daily 7
  • Increase by 300 mg every 3 days 7
  • Prescription Template:
    Oxcarbazepine 300 mg PO BID
    Increase to 600 mg BID after 3 days
    Then 900 mg BID after 3 more days
    Target maintenance: 900-1200 mg BID
    Monitor: Sodium (hyponatremia risk), rash

Option 2: Carbamazepine (Treatment of Choice)

  • Starting dose: 200 mg twice daily 7, 8
  • Increase by 200 mg every week 8
  • Therapeutic level: 4-12 μg/mL 8
  • Prescription Template:
    Carbamazepine 200 mg PO BID
    Increase to 400 mg BID after 1 week
    Then 600 mg BID after 1 more week
    Target maintenance: 800-1200 mg daily in 2-3 divided doses
    Monitor: CBC, liver function, carbamazepine level, sodium
    Check for HLA-B*1502 in Asian patients before starting

Option 3: Lamotrigine (First-Line Alternative)

  • Starting dose: 25 mg daily for 2 weeks 7, 4, 5
  • Prescription Template:
    Lamotrigine 25 mg PO daily x 2 weeks
    Then 50 mg daily x 2 weeks
    Then 100 mg daily x 1 week
    Target maintenance: 200-400 mg daily in 1-2 divided doses
    Monitor: Rash (discontinue if develops)

Option 4: Levetiracetam (First-Line Alternative)

  • Starting dose: 500 mg twice daily 7, 4, 5
  • Prescription Template:
    Levetiracetam 500 mg PO BID
    Increase to 1000 mg BID after 2 weeks
    Target maintenance: 1000-1500 mg BID
    Monitor: Behavioral changes, irritability

Adjunctive Therapy (If Monotherapy Fails)

For partial seizures refractory to monotherapy, add one of the following to the initial agent: 9

Valproate Added to Carbamazepine/Oxcarbazepine

  • Prescription Template:
    Continue current carbamazepine/oxcarbazepine dose
    Add Valproic Acid 250 mg PO TID
    Increase by 250 mg weekly
    Target: 1000-1500 mg daily in divided doses
    Monitor: Drug levels, liver function, drug interactions

Lamotrigine Added to Carbamazepine/Oxcarbazepine

  • Prescription Template:
    Continue current carbamazepine/oxcarbazepine dose
    Add Lamotrigine 25 mg PO daily x 2 weeks
    Then 50 mg daily x 2 weeks
    Target: 200-400 mg daily
    Monitor: Rash, drug interactions

Alternative Add-On Options

  • Gabapentin: 300 mg TID, increase to 900-1800 mg TID 9
  • Topiramate: 25 mg daily, increase to 200-400 mg daily in divided doses 9
  • Vigabatrin: Consider for refractory cases 9

Simple Partial Seizures (Focal Aware Seizures)

Simple partial seizures follow the same treatment algorithm as complex partial seizures, with carbamazepine, oxcarbazepine, lamotrigine, and levetiracetam as first-line options. 7, 4, 5

First-Line Treatment

  • Use identical prescribing templates as Complex Partial Seizures above 7, 4, 5
  • Oxcarbazepine 300 mg BID titrated to 900-1200 mg BID 7
  • Carbamazepine 200 mg BID titrated to 800-1200 mg daily 7, 8
  • Lamotrigine 25 mg daily titrated to 200-400 mg daily 7, 4, 5
  • Levetiracetam 500 mg BID titrated to 1000-1500 mg BID 7, 4, 5

Absence Seizures

For childhood absence epilepsy, ethosuximide is the treatment of choice, with valproate and lamotrigine also as first-line options. 7

Childhood Absence Epilepsy

Option 1: Ethosuximide (Treatment of Choice)

  • Starting dose: 250 mg daily 7
  • Increase gradually to therapeutic effect 7
  • Prescription Template:
    Ethosuximide 250 mg PO daily
    Increase to 250 mg BID after 1 week
    Target maintenance: 500-750 mg daily in 2 divided doses
    Monitor: CBC, liver function, ethosuximide level
    Therapeutic level: 40-100 μg/mL

Option 2: Valproate (First-Line Alternative)

  • Starting dose: 15 mg/kg/day in divided doses 6, 7
  • Prescription Template:
    Valproic Acid 250 mg PO BID (for 30 kg child = 16.7 mg/kg/day)
    Increase by 250 mg weekly as tolerated
    Target: 500-1000 mg daily in divided doses
    Monitor: Liver function, CBC, ammonia, valproate level
    Therapeutic level: 50-100 μg/mL

Option 3: Lamotrigine (First-Line Alternative)

  • Starting dose: 25 mg daily for 2 weeks 7
  • Prescription Template:
    Lamotrigine 25 mg PO daily x 2 weeks
    Then 50 mg daily x 2 weeks
    Target maintenance: 100-200 mg daily in 1-2 divided doses
    Monitor: Rash (discontinue if develops)

Juvenile Absence Epilepsy

For juvenile absence epilepsy, valproate and lamotrigine are treatments of choice. 7

Option 1: Valproate (Treatment of Choice for Males)

  • Use same dosing as above 7
  • Prescription Template:
    Valproic Acid 250 mg PO TID
    Increase by 250 mg weekly
    Target: 1000-1500 mg daily in divided doses
    Monitor: Liver function, CBC, valproate level

Option 2: Lamotrigine (Treatment of Choice for Females)

  • Use same dosing as childhood absence 7
  • Prescription Template:
    Lamotrigine 25 mg PO daily x 2 weeks
    Then 50 mg daily x 2 weeks
    Target maintenance: 200-400 mg daily
    Monitor: Rash

Atypical Absence Seizures

For atypical absence seizures, valproate and lamotrigine are recommended. 9

  • Use same prescribing templates as typical absence seizures above 9
  • Consider combination therapy if monotherapy fails 9

Juvenile Myoclonic Epilepsy

For juvenile myoclonic epilepsy in adolescent males, valproate and lamotrigine are treatments of choice, with topiramate also first-line; for adolescent females, lamotrigine is treatment of choice. 7

For Adolescent Males

Option 1: Valproate (Treatment of Choice)

  • Starting dose: 15 mg/kg/day in divided doses 6, 7
  • Prescription Template:
    Valproic Acid 250 mg PO TID
    Increase by 250 mg weekly
    Target: 1000-2000 mg daily in divided doses
    Monitor: Liver function, CBC, valproate level
    Therapeutic level: 50-100 μg/mL

Option 2: Lamotrigine (Treatment of Choice)

  • Starting dose: 25 mg daily for 2 weeks 7
  • Prescription Template:
    Lamotrigine 25 mg PO daily x 2 weeks
    Then 50 mg daily x 2 weeks
    Then 100 mg daily x 1 week
    Target maintenance: 200-400 mg daily
    Monitor: Rash

Option 3: Topiramate (First-Line)

  • Starting dose: 25-50 mg daily 7
  • Prescription Template:
    Topiramate 25 mg PO daily x 1 week
    Then 50 mg daily x 1 week
    Then 100 mg daily x 1 week
    Target maintenance: 200-400 mg daily in 2 divided doses
    Monitor: Cognitive effects, weight loss

For Adolescent Females (Childbearing Potential)

Option 1: Lamotrigine (Treatment of Choice)

  • Use same dosing as above 7
  • Avoid valproate due to teratogenicity 7, 4, 5

Option 2: Topiramate (First-Line Alternative)

  • Use same dosing as above 7

Option 3: Levetiracetam (First-Line Alternative)

  • Starting dose: 500 mg twice daily 4, 5
  • Prescription Template:
    Levetiracetam 500 mg PO BID
    Increase to 1000 mg BID after 2 weeks
    Target maintenance: 1000-1500 mg BID
    Monitor: Behavioral changes

Special Populations and Considerations

Elderly Patients

Due to decreased unbound clearance and greater sensitivity to somnolence, start with reduced doses in elderly patients and increase more slowly with regular monitoring. 6

  • Valproate: Start at 250 mg daily, increase by 125-250 mg weekly 6
  • Levetiracetam: Start at 250 mg BID, increase by 250 mg every 2 weeks 6
  • Monitor for dehydration, decreased food/fluid intake, and excessive somnolence 6

End-Stage Renal Disease

For patients with ESRD and subtherapeutic valproate levels, increase dose from 500 mg daily to at least 750-1000 mg daily (15-20 mg/kg/day range). 10

Levetiracetam may be superior in ESRD patients due to predictable dosing adjustments for dialysis. 10

  • Levetiracetam in ESRD: 500-1000 mg daily with supplemental doses after dialysis 10

Critical Pitfalls to Avoid

Status Epilepticus Management

  • Never use neuromuscular blockers alone (e.g., rocuronium) as they only mask motor manifestations while allowing continued electrical seizure activity and brain injury 1
  • Do not skip to third-line agents (pentobarbital) until benzodiazepines and a second-line agent have been tried 1
  • Simultaneously search for and treat underlying causes: hypoglycemia, hyponatremia, hypoxia, drug toxicity, CNS infection, ischemic stroke, intracerebral hemorrhage, withdrawal syndromes 1

Chronic Seizure Management

  • Avoid phenobarbital and phenytoin as first-choice drugs for long-term management due to sedative effects and cognitive/cerebellar dysfunction 9
  • Monitor for thrombocytopenia with valproate at levels above 110 μg/mL (females) or 135 μg/mL (males) 6
  • Avoid valproate in women of childbearing potential when possible due to teratogenicity 4, 5
  • Do not abruptly discontinue antiepileptic drugs due to risk of precipitating status epilepticus 6
  • Check HLA-B*1502 in Asian patients before starting carbamazepine due to Stevens-Johnson syndrome risk 8

Monitoring Requirements

  • Continuous vital sign monitoring is essential during acute treatment, particularly respiratory status and blood pressure 1
  • Prepare for respiratory support regardless of administration route 1
  • EEG monitoring should guide titration in refractory status epilepticus to achieve seizure suppression 1

References

Guideline

Status Epilepticus Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Tonic-Clonic Seizures

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Treatment of pediatric epilepsy: expert opinion, 2005.

Journal of child neurology, 2005

Research

Use of antiepileptic drugs in the treatment of epilepsy in people with intellectual disability.

Journal of intellectual disability research : JIDR, 1998

Guideline

Managing Valproate Therapy in Patients with End-Stage Renal Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.